ATHENA-I-Capsid-Library-2.png
AAV Capsid Barcode Kit-Myo
AAV Capsid Barcode Kit-Myo
  1. ATHENA-I-Capsid-Library-2.png
  2. AAV Capsid Barcode Kit-Myo
  3. AAV Capsid Barcode Kit-Myo

AAV Capsid Barcode Kit-Myo

Price range: $9,999.00 through $49,999.00

AAV Capsid Barcode Kit-Myo is designed to systematically evaluate different AAV serotypes or myotropic AAV variants in muscle and heart tissues. This library includes a combination of 15 common AAV capsids and 9 reported myotropic AAV capsids, providing researchers with a comprehensive set of tools for targeted gene delivery to the muscle. Researchers can conduct comparative studies to assess the transduction efficiency, specificity, and safety profiles of different AAV capsids when administered to muscle tissues.

  • SKU: DH005001M
  • AAV Expression Cassette: AAV-CAG-EGFP-WPRE-BCs-bGHpolyA.
  • AAV Capsid List:
  • AAV status: Mixed viruses.
  • AAV Titer: ~1X10^13 VG/ml
  • BC design: (N)12-ACGGAAATACGATGTCGGGA-(N)12
  • Production: One AAV capsid and assigned 3 barcode plasmids were co-transfected to make one specific capsid AAV vector.
  • Purification: Each AAV capsid were produced(HEK 293T), purification(two rounds of CsCl) and titration(qPCR), separately.
  • Storage Buffer: 0.001% F-68/DPBS with additional 150mM NaCl.
  • Storage:  -80°C for long term (> 1 year);  -20°C for short term(1-2 months);  4 °C for 1-2 weeks.
  • Shipping: Dry ice.
Add to Quote
SKU: DH005001M Category: Tags: , , , , , , , ,

AAV Capsid Barcode Kits-Tissues

Tissue-specific AAV capsid Barcode Kits are designed to systematically evaluate AAV capsid variants that have been engineered to exhibit enhanced tropism for specific target tissues. It also includes 15 commonly used AAV serotypes that serve as controls, which are essential for benchmarking and comparative purposes.

ImageNameSKUTagsPriceBuyhf:tags

AAV Capsid Barcode Kits-Common

Common AAV Capsids: AAV1, AAV2, AAV3B,  AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, AAV12, AAV13, AAVrh.74, AAV-DJ, AAV2-Retro

ImageNameSKUPriceBuy

Design of AAV Capsid Barcode Kits

AAV Capsid Barcode Kits are known AAV capsid selection kits build on our ATHENA I platform. In the ATHENA I, each capsid variant is associated with three different DNA-barcoded genomes, and all three of these genomes carry the same reporter gene. The use of three DNA barcodes for one capsid variant can minimize experimental variations and improve the accuracy of the results in high-throughput screening or selection processes.

In the AAV Capsid Barcode Kits,  AAV genomes carried different  promoters and different reporter genes, such as AAV-CAG-EGFP, AAV-CMV-mCherry, and scAAV-CMV-mCherry. The presence of the reporter gene allows for the enrichment of transgene-expressing cells, making it possible to identify and isolate cells that have taken up and expressed the AAV genomes.

The unique barcodes  are located before Poly signal. NGS technology is used to analyze the barcode data after AAV infection or injection.  Researchers can use the unique DNA barcodes to evaluate the distribution of each capsid variant for different types of target cells. This screening method helps identify which AAV capsids are most effective at transducing specific cell types. In addition to DNA barcode screening, transcribed RNA barcodes can be evaluated to assess the potential of different capsids for each target cell. This approach provides insights into the transcriptional activity of the AAV genomes in the context of specific cell types.

Common AAV Capsid List: AAV1, AAV2, AAV3B,  AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, AAV12, AAV13, AAVrh.74, AAV-DJ, AAV2-Retro

ATHENA I Known Capsid Library

Example 1:

AAV Capsid Kit: AAV Capsid Barcode Kit-Common-CAG-EGFP

Animal model: C57B6

Injection Route:  IV injection

Time Point: 2 weeks post injection

Analysis method: NGS for BCs

Results: Fold enrichment compared with input AAV viruses

AAV Capsid Library(I)-Common

References:

  1. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Weinmann J, Weis S, Sippel J, Tulalamba W, Remes A, El Andari J, Herrmann AK, Pham QH, Borowski C, Hille S, Schönberger T, Frey N, Lenter M, VandenDriessche T, Müller OJ, Chuah MK, Lamla T, Grimm D.Nat Commun. 2020 Oct 28;11(1):5432. doi: 10.1038/s41467-020-19230-w.
  2. 2. Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.El Andari J, Renaud-Gabardos E, Tulalamba W, Weinmann J, Mangin L, Pham QH, Hille S, Bennett A, Attebi E, Bourges E, Leborgne C, Guerchet N, Fakhiri J, Krämer C, Wiedtke E, McKenna R, Guianvarc’h L, Toueille M, Ronzitti G, Hebben M, Mingozzi F, VandenDriessche T, Agbandje-McKenna M, Müller OJ, Chuah MK, Buj-Bello A, Grimm D.Sci Adv. 2022 Sep 23;8(38):eabn4704. doi: 10.1126/sciadv.abn4704. Epub 2022 Sep 21.
  3. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, Krunnfusz A, Tavakoli S, Widrick JJ, Messemer KA, Troiano EC, Moghadaszadeh B, Peacker BL, Leacock KA, Horwitz N, Beggs AH, Wagers AJ, Sabeti PC.Cell. 2021 Sep 16;184(19):4919-4938.e22. doi: 10.1016/j.cell.2021.08.028. Epub 2021 Sep 9.
  4. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C, Pu D, Hu X, Wang DZ, Li J, Xiao X.Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3946-51. doi: 10.1073/pnas.0813207106. Epub 2009 Feb 20.
  5. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, Samulski RJ.Nat Biotechnol. 2010 Jan;28(1):79-82. doi: 10.1038/nbt.1599. Epub 2009 Dec 27.
AAV Scale

1X10^12 VG/Capsid, 2X10^12 VG/Capsid, 5X10^12 VG/Capsid, 10X10^12 VG/Capsid

Related products